亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer—Final results at 20-year follow-up

医学 三苯氧胺 乳腺癌 乳房切除术 人口 肿瘤科 外科 癌症 内科学 妇科 环境卫生
作者
Jayeta Chakrabarti,Frances Kenny,Binafsha Manzoor Syed,J. F. R. Robertson,R. W. Blamey,Kwok-Leung Cheung
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:78 (3): 260-264 被引量:53
标识
DOI:10.1016/j.critrevonc.2010.04.006
摘要

A recent Cochrane review of trials involving elderly women with operable primary breast cancer showed no significant difference in overall survival between surgery (±adjuvant tamoxifen) and primary endocrine therapy using tamoxifen. We report the final results of a randomised pilot trial comparing primary tamoxifen and wedge mastectomy as initial treatment in this population. One hundred and thirty-one women >70 years with early operable primary breast cancer (<5 cm), unselected for oestrogen receptor (ER), entered the trial in 1982-1987. Sixty-eight patients were allocated to tamoxifen only and 67 to wedge mastectomy only, as primary treatment. At 20 years of follow-up, the median time to local failure was significantly shorter in the tamoxifen arm though approximately one-fifth of patients in this group did not develop local failure requiring mastectomy. There was no difference in regional recurrence, distant metastases or overall survival between the mastectomy and tamoxifen arms. In this small study, primary endocrine therapy achieved local control in 30% of those surviving at 5 years and 20% at 10 years, unselected for ER. The primary therapy used did not significantly affect regional recurrence, incidence of distant metastases or overall survival. Primary endocrine therapy should certainly be considered in those patients with ER positive tumours and who are unfit (based on life expectancy) for or refuse surgery.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas的应助被科研通管家采纳,获得10
刚刚
852的应助被科研通管家采纳,获得10
1秒前
共享精神的应助被科研通管家采纳,获得10
1秒前
殷宵箫发布了新的文献求助10
1秒前
英姑的应助被科研通管家采纳,获得10
1秒前
含蓄的芝麻完成签到,获得积分10
3秒前
ADAB0002完成签到,获得积分10
4秒前
果冻完成签到 ,获得积分10
5秒前
5秒前
vfdhjng完成签到,获得积分20
7秒前
7秒前
可爱的函函的应助被lx采纳,获得10
9秒前
10秒前
华仔的应助被怡宝采纳,获得10
11秒前
summerer发布了新的文献求助20
12秒前
13秒前
嘻嘻哈哈的应助被Gloria采纳,获得10
13秒前
费洛蒙漩涡完成签到,获得积分10
14秒前
孤独孤风完成签到,获得积分10
14秒前
苹果颖完成签到,获得积分10
15秒前
lx完成签到,获得积分10
16秒前
17秒前
17秒前
科研通AI6.4的应助被殷宵箫采纳,获得10
17秒前
18秒前
鱼鱼鱼完成签到,获得积分10
20秒前
lx发布了新的文献求助10
22秒前
22秒前
顺心尔冬完成签到,获得积分10
22秒前
23秒前
康子浩发布了新的文献求助10
23秒前
cong发布了新的文献求助10
25秒前
科研通AI6.2的应助被追寻芷采纳,获得10
27秒前
vfdhjng关注了科研通微信公众号
29秒前
七七完成签到,获得积分10
31秒前
31秒前
礼拜一发布了新的文献求助10
35秒前
淮安石河子完成签到 ,获得积分10
36秒前
坚强含烟完成签到,获得积分10
41秒前
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165846
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749858
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553354
邀请新用户注册赠送积分活动 2473622